| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/06/2004 | WO2002022150A3 Medicament containing activated antithrombin iii |
| 05/06/2004 | WO2001074296A3 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 05/06/2004 | US20040087784 Neuronal serine-threonine protein kinase |
| 05/06/2004 | US20040087662 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| 05/06/2004 | US20040087661 Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine |
| 05/06/2004 | US20040087656 Controlling particle size; efficient pharmokinetics profile; surface stabilizer; bioadhesive |
| 05/06/2004 | US20040087653 Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor |
| 05/06/2004 | US20040087645 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| 05/06/2004 | US20040087642 Kinase inhibitor; immunosuppressants; anticonvulsants; using indazole compound |
| 05/06/2004 | US20040087640 Administering by mouth; cyclooxygenase inhibitor; controlling particle size |
| 05/06/2004 | US20040087635 Administering insulin sensitizer; benign prostatic hyperplasia |
| 05/06/2004 | US20040087630 Combinations |
| 05/06/2004 | US20040087626 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
| 05/06/2004 | US20040087616 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| 05/06/2004 | US20040087611 Cancer treatment by combination therapy |
| 05/06/2004 | US20040087610 Method and composition for the treatment of cancer |
| 05/06/2004 | US20040087607 Adjust intensity of analgesics; blocking gangliosides |
| 05/06/2004 | US20040087599 cGMP-PDE inhibitors for the treatment of erectile dysfunction |
| 05/06/2004 | US20040087592 Treatment of malaria with farnesyl protein transferase inhibitors |
| 05/06/2004 | US20040087579 Antitumor agents, anticancer agents; synergistic mixture; side effect reduction |
| 05/06/2004 | US20040087561 Treatment of sexual dysfunction |
| 05/06/2004 | US20040087558 Analgesics; antiarthritic agents; osteoporosis |
| 05/06/2004 | US20040087557 Treating muscle wasting with selective androgen receptor modulators |
| 05/06/2004 | US20040087555 Phosphohalohydrins, process for the production thereof and use thereof |
| 05/06/2004 | US20040087546 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
| 05/06/2004 | US20040087538 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1 |
| 05/06/2004 | US20040087518 Rehydration composition |
| 05/06/2004 | US20040087515 Compositions methods for improving cardio vascular function |
| 05/06/2004 | US20040087513 Cardiac or cerebral ischemias; strokes |
| 05/06/2004 | US20040087510 Cardiovascular diseases and disorders; sustained delivery of nitric oxide |
| 05/06/2004 | US20040087497 CD10-activated prodrug compounds |
| 05/06/2004 | US20040087486 Inhibiting vascular occlusive events; reducing circulating count below normal levels without serious adverse consequence |
| 05/06/2004 | US20040087484 Treating sexual dysfunction associated with hypertension; angiotensin receptor blocker with either antihypertensive agent or HMG-CoA reductase inhibitor |
| 05/06/2004 | US20040087478 Discovering pain regulating substances; incubating with then measuring binding to cell synthesized peptide or protein |
| 05/06/2004 | US20040087035 Using myeloproliferative leukemic inhibitory agents to treatment and/ or prevention platelet related thrombotic and vaso-occlusive disorder |
| 05/06/2004 | US20040086937 Screening for antagonists and/or inhibitors of bacterial propagation and infection; mimetics |
| 05/06/2004 | US20040086923 Comprises polypeptide with carbamoyl phosphate synthase (CPS) activity for identifying modulators which prevent and/or treat cancer and metabolic disorders |
| 05/06/2004 | US20040086913 Human genes and gene expression products XVI |
| 05/06/2004 | US20040086905 Lipid-associated molecules |
| 05/06/2004 | US20040086904 Identifying modulators which suppress synthesis of secreted and/or membrane protein for prevention and treatment of allergic,inflammatory, skin, cardiovascular, nervous system and cancer disorders |
| 05/06/2004 | US20040086877 Multi-mode directi memory access controller and method |
| 05/06/2004 | US20040086863 Comprises pleckstrin homology domain-interacting protein (PHI Protein) for identifying modulator and treatment for cancer and insulin response disorders |
| 05/06/2004 | US20040086854 Drug metabolizing enzymes |
| 05/06/2004 | US20040086585 Composition and methods for treating Alzheimer's disease and other amyloidoses |
| 05/06/2004 | US20040086578 Physiologically acceptable aqueous solutions and methods for their use |
| 05/06/2004 | US20040086574 Iron-free multi-vitamin/mineral/antioxidant formulation, designed to optimize health and wellness, minimize oxidative stress, and normalize homocysteine levels |
| 05/06/2004 | US20040086571 For therapy of dyslipidemia and dyslipoproteinemia |
| 05/06/2004 | US20040086562 Orally administering to a patient a spaced drug delivery system, wherein first therapeutically active agent is released immediately and second therapeutically active agent is released as a pulse at predetermined time after administration |
| 05/06/2004 | US20040086561 For preventing oral abuse of an oral opioid formulation |
| 05/06/2004 | US20040086536 Comprising an anticholinergic agent and an NO donor as the active ingredients |
| 05/06/2004 | US20040086516 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling |
| 05/06/2004 | US20040086514 Based on the finding of a specific Helicobacter pylori receptor in the human gastric epithelium; a glycolipid, lactotetraosylceramide, exclusively found in the human gastrointestinal tract |
| 05/06/2004 | US20040086503 High-affinity human anti-IGF-IR antibodies that could be used to treat diseases in humans |
| 05/06/2004 | US20040086500 Murabutide, an analog of muramyl dipeptide, induces the production of cytokines or other factors not identified to date, which have a suppressor activity on HIV |
| 05/06/2004 | US20040086498 Cancer therapy |
| 05/06/2004 | US20040086479 Can be chemically modified for different biomedical applications such as tissue engineering applications, wound management, contrast agents vehicles, drug delivery vehicles, etc. |
| 05/06/2004 | EP1416281A2 Assay for disease related conformation of a protein |
| 05/06/2004 | EP1416272A1 Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson's disease |
| 05/06/2004 | EP1416048A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-;defective splicing variant |
| 05/06/2004 | EP1415668A1 Remedies for brain ischemic diseases |
| 05/06/2004 | EP1415661A1 Homing of embryonic stem cells to a target zone in tissue for delivery of translocation stimulators |
| 05/06/2004 | EP1415659A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/06/2004 | EP1415653A2 Use of progesterone or an agonist thereof for the inhibition of steroid synthesis |
| 05/06/2004 | EP1415650A1 Nutritional composition for the prevention and treatment of cachexia and anorexia |
| 05/06/2004 | EP1415647A1 "Long-acting beta-2 agonists ultrafine formulations" |
| 05/06/2004 | EP1415005A2 Endogenous retroviruses up-regulated in prostate cancer |
| 05/06/2004 | EP1414967A2 Gene associated with leishmania parasite virulence |
| 05/06/2004 | EP1414965A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/06/2004 | EP1414964A2 Vegf isoform |
| 05/06/2004 | EP1414963A2 Lipid-associated molecules |
| 05/06/2004 | EP1414853A2 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 05/06/2004 | EP1414851A2 Cellular virus receptors and methods of use. |
| 05/06/2004 | EP1414820A1 Non-nucleoside reverse transcriptase inhibitors |
| 05/06/2004 | EP1414809A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 05/06/2004 | EP1414804A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/06/2004 | EP1414797A2 Hepatitis c virus polymerase inhibitors with a heterobicylic structure |
| 05/06/2004 | EP1414526A2 Antiangiogenic combination therapy for the treatment of cancer |
| 05/06/2004 | EP1414522A2 Carbonic anhydrase inhibitors |
| 05/06/2004 | EP1414496A1 Oral pharmaceutical composition containing a combinaition of ppar-alpha and a hmg-coa reductase inhibitor |
| 05/06/2004 | EP1414494A1 Inhibitors of her3 activity |
| 05/06/2004 | EP1414491A2 Methods of inhibiting amyloid toxicity |
| 05/06/2004 | EP1414489A2 Antiallergic pharmaceutical composition |
| 05/06/2004 | EP1414486A2 Use of glp-2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 05/06/2004 | EP1414484A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome |
| 05/06/2004 | EP1414481A2 Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 05/06/2004 | EP1414479A1 Peptide for regulation of tissue plasminogen activator |
| 05/06/2004 | EP1414478A2 Inhibition of neurodegeneration |
| 05/06/2004 | EP1414474A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 05/06/2004 | EP1414471A2 Therapeutic agents comprising pro-apoptotic proteins |
| 05/06/2004 | EP1414469A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 05/06/2004 | EP1414467A2 Topical treatment for mastalgia |
| 05/06/2004 | EP1414466A1 Combinations for the treatment of inflammatory disorders |
| 05/06/2004 | EP1414465A2 Use of inhibitors of progesterone receptor for treating cancer |
| 05/06/2004 | EP1414459A1 Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| 05/06/2004 | EP1414452A1 Novel substituted benzimidazole dosage forms and method of using same |
| 05/06/2004 | EP1414451A1 Opioid agonist formulations with releasable and sequestered antagonist |
| 05/06/2004 | EP1414446A1 Pramipexol as an anticonvulsive agent |
| 05/06/2004 | EP1414445A1 Partial agonists at the glycine modulatory site of the nmda receptor for treating cognitive dysfunction |
| 05/06/2004 | EP1414441A2 Hepatitis c virus polymerase inhibitors with heterobicyclic structure |
| 05/06/2004 | EP1414439A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |